Slide 1: Courageous Innovation Q1 2022 Update
Courageous Innovation Q1 2022 Update May 2022 NASDAQ: OCGN
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “c
Slide 3: We're Here to Make an Impact Through Courageous Innovation
We’re Here to Make an Impact Through Courageous Innovation 3
Slide 4: Business update on COVAXIN (BBV152)
4 Business update on COVAXIN™ (BBV152) The Company is working with the FDA to address questions arising from WHO’s inspection of BBIL’s manufacturing facility in order to continue with OCU- 002 clinical trial Planning to commercialize COVAXIN™ in Mexico in 2022, following the broadening of the Ocuge
Slide 5: Business update on the Ophthalmology Portfolio
5 Business update on the Ophthalmology Portfolio First and second patients dosed in Phase 1/2 clinical trial studying OCU400 for the treatment of retinitis pigmentosa resulting from genetic mutations of NR2E3 and RHO Data Monitoring and Safety Board recommended OCU400-101 clinical trial to proceed w
Slide 6: Financial Update
Financial Update 6
Slide 7: Financial Update
7 Financial Update Statement of Operations Three months ended March 31, 2022 2021 Research and development expense $7.9 $2.9 General and administrative expense 10.1 4.2 Net loss $(18.0) $(7.1) Net loss per share of common stock — basic and diluted $(0.09) $(0.04) Balance Sheet Data March 31, 2022 De
Slide 8: Questions & Answers
Questions & Answers 8
Slide 9: Thank you!
May 2022 NASDAQ: OCGN Thank you!